Payment overview · 2025
General Payments
$23.05
1 reported records · 1 companies
Healthcare provider profile · identity verified
David Rainosek, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LITTLE ROCK, AR · NPI 1326359472
Verified facts
What the public records show
CMS Open Payments records show David Rainosek, M.D. received $23.05 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Qulipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.05 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $23.05 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 628 | 75 |
| Gabapentin | Gabapentin | 510 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 498 | 52 |
| Eliquis | Apixaban | 399 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 364 | 35 |
| Furosemide | Furosemide | 344 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 50 |
| Metformin Hcl | Metformin Hcl | 235 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 25 |
| Potassium Chloride | Potassium Chloride | 214 | 31 |
| Baclofen | Baclofen | 188 | 20 |
| Carvedilol | Carvedilol | 180 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 25 |
| Losartan Potassium | Losartan Potassium | 156 | 24 |
| Sertraline Hcl | Sertraline Hcl | 151 | 23 |
| Trazodone Hcl | Trazodone Hcl | 149 | 23 |
| Levetiracetam | Levetiracetam | 143 | 21 |
| Lisinopril | Lisinopril | 137 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | suppressed |
| Famotidine | Famotidine | 119 | 15 |
| Mirtazapine | Mirtazapine | 118 | 25 |
| Divalproex Sodium | Divalproex Sodium | 112 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 19 |
| Nifedipine Er | Nifedipine | 105 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 12 |
| Jardiance | Empagliflozin | 84 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 13 |
| Xarelto | Rivaroxaban | 78 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 33 |
| Omeprazole | Omeprazole | 72 | 11 |
| Donepezil Hcl | Donepezil Hcl | 71 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 70 | suppressed |
| Bumetanide | Bumetanide | 70 | 15 |
| Montelukast Sodium | Montelukast Sodium | 69 | suppressed |
| Memantine Hcl | Memantine Hcl | 67 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 19 |
| Midodrine Hcl | Midodrine Hcl | 57 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Allopurinol | Allopurinol | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 49 | suppressed |
| Sucralfate | Sucralfate | 49 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 49 | 22 |
| Torsemide | Torsemide | 46 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Olanzapine | Olanzapine | 45 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 11 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | suppressed |
| Prednisone | Prednisone | 42 | 13 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Novolog | Insulin Aspart | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Lactulose | Lactulose | 39 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | 11 |
| Insulin Lispro | Insulin Lispro | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 18 |
| Admelog | Insulin Lispro | 25 | suppressed |
| Calcium Acetate | Calcium Acetate | 25 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 24 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 23 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Dofetilide | Dofetilide | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Acetylcysteine | Acetylcysteine | 20 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Novolin R | Insulin Regular, Human | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 18 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Qulipta | Atogepant | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Tivicay | Dolutegravir Sodium | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Insulin Lispro Junior Kwikpen | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23.05 · 1 records | ABBVIE INC. | AVYCAZ, TEFLARO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error